Peer-influenced content. Sources you trust. No registration required. This is HCN.
Gastroenterology Advisor
Continuous mirikizumab treatment demonstrated durable efficacy across multiple outcome measures for over three years, with 70.1% of week-52 remitters maintaining clinical remission at week 152 and comparable quality of life improvements in both biologic-naïve and biologic-failure patients.
Gastroenterology May 1st 2025